NSE: ZYDUSLIFE | BSE: 532321

Falling Comet

Download real time

883.15 14.30 (1.65%)

33.31% Fall from 52W High

1.6M NSE+BSE Volume

NSE 15 Apr, 2025 3:31 PM (IST)

88,865.6

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

US FDA Approval

Zydus Life receives final approval from the US FDA to manufacture Jaythari (Deflazacort) tablets See details

Zydus Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ZYDUSLIFE, BSE:532321 Zydus Lifesciences Ltd.

Search Inside the pdf :

Zydus Lifesciences Ltd.

07 Feb 2025

883.15

1.65%

New product launches is set to drive growth in US

Buy: Zydus Lifesciences Ltd.

KRChoksey

Zydus Lifesciences’ revenue was largely in-line with our estimates. EBITDA missed our estimates due to lower-than-expected gross profit and higher-than-expected other expenses. However, Adj. PAT was in-line with our estimates as EBITDA miss was offset by lower-than-expected tax expenses.

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

06 Feb 2025

883.15

1.65%

Near-term challenges persist in US

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings.

Zydus Lifesciences L.. has an average target of 1089.17 from 6 brokers.

Zydus Lifesciences Ltd.

06 Feb 2025

883.15

1.65%

ZYDUS LIFESCIENCES L

Accumulate: Zydus Lifesciences Ltd.

Target

Prabhudas Lilladhar

Zydus Lifesciences L.. has an average target of 1089.17 from 6 brokers.

Zydus Lifesciences Ltd.

18 Nov 2024

883.15

1.65%

Sustained Growth Across All Segments

Buy: Zydus Lifesciences Ltd.

Target

Sharekhan

Revenue amounted to Rs. 5,237 crore, reflecting a 20% y-o-y increase but a 16% q-o-q decline,
primarily driven by reduced performance in the Indian consumer wellness segment, US
formulations and API business.

Zydus Lifesciences L.. has an average target of 1089.17 from 6 brokers.

Zydus Lifesciences Ltd.

13 Nov 2024

883.15

1.65%

Ongoing litigation and regulatory hurdles weigh on valuation

Buy: Zydus Lifesciences Ltd.

Target

KRChoksey

Zydus Lifesceinces’ revenue was largely in-line with our estimate (-2.7%) due to strong growth across geographical segments. However, Adj. PAT missed our estimate due to higher-than-expected depreciation and tax expenses, and lower-than-expected other income.

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

12 Nov 2024

883.15

1.65%

The US and international markets drive earnings

Neutral: Zydus Lifesciences Ltd.

Target

Motilal Oswal

Zydus LifeSciences (ZYDUSLIF) delivered better-than-expected operational
performance for the quarter. While its revenue grew at a lower rate of 19% YoY (vs. est. of 25%).

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

03 Oct 2024

883.15

1.65%

R&D advancements to drive growth

Buy: Zydus Lifesciences Ltd.

Target

Sharekhan

Zydus Lifesciences Ltd has partnered with the Central Drug Research Institute (CDRI) to develop an oral
treatment for osteoporosis related to chronic kidney disease (CKD) and postmenopausal conditions, focusing on small-molecule inhibitors of the protein sclerostin.

Zydus Lifesciences L.. has an average target of 1089.17 from 6 brokers.

Zydus Lifesciences Ltd.

21 Aug 2024

883.15

1.65%

Improved products mix to drive profitability

Buy: Zydus Lifesciences Ltd.

Recommendation Target

KRChoksey

The growth in revenue from operations was driven by a strong 26.0% Y-o-Y (+22.6% Q-o-Q) growth in the US market to INR 30,929 Mn (estimated: INR 31,846 Mn); It was driven by new launches such as Mirabegron, Zituvimet and volume expansion in the base portfolio as gRevlimid also improved Q-o-Q.